Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: GNT002
MIFTS: 50

Giant Cell Glioblastoma

Categories: Bone diseases, Cancer diseases, Neuronal diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Giant Cell Glioblastoma

About this section

MalaCards integrated aliases for Giant Cell Glioblastoma:

Name: Giant Cell Glioblastoma 12 58 54 15 71
Monstrocellular Sarcoma 12 71

Characteristics:

Orphanet epidemiological data:

58
giant cell glioblastoma
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases Bone diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:3074
MeSH 43 D005909
NCIt 49 C4325
SNOMED-CT 67 44529004
ICD10 via Orphanet 33 C71.9
UMLS via Orphanet 72 C0334588
Orphanet 58 ORPHA251579
UMLS 71 C0334588 C0334593
Sources

Summaries for Giant Cell Glioblastoma

About this section
Disease Ontology : 12 A glioblastoma multiforme that is characterized by a prevalence of bizarre, multinucleated giant cells.

MalaCards based summary : Giant Cell Glioblastoma, also known as monstrocellular sarcoma, is related to glial tumor and glioblastoma multiforme, and has symptoms including seizures and headache. An important gene associated with Giant Cell Glioblastoma is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are Class I MHC mediated antigen processing and presentation and GAB1 signalosome. The drugs Trioxsalen and Donepezil have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and prostate, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 The giant-cell glioblastoma is a histological variant of glioblastoma, presenting a prevalence of... more...

Sources

Related Diseases for Giant Cell Glioblastoma

About this section

Diseases related to Giant Cell Glioblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 337)
# Related Disease Score Top Affiliating Genes
1 glial tumor 31.2 PTEN IDH1
2 glioblastoma multiforme 30.7 TP53 SYP PTEN PPARG NFKBIA MGMT
3 pleomorphic xanthoastrocytoma 30.7 TP53 SYP SERPINA3 MGMT IDH1 GFAP
4 papilloma of choroid plexus 30.6 TP53 SYP GFAP
5 spindle cell sarcoma 30.5 SERPINA3 MDM2 CD34
6 glioma 30.5 TP53 PTEN PPARG MDM2 IDH1 FGFR1
7 ganglioglioma 30.5 TP53 SYP IDH1 GFAP
8 papilloma 30.5 TP53 PTEN FGFR3 EGFR
9 gemistocytic astrocytoma 30.3 TP53 PTEN MGMT IDH1 GFAP
10 grade iii astrocytoma 30.0 TP53 SERPINA3 PTEN MGMT MDM2 IDH1
11 hydrocephalus 30.0 TP53 SYP SERPINA3 PTEN GFAP FGFR3
12 fibrillary astrocytoma 30.0 TP53 SERPINA3 PTEN MGMT IDH1 GFAP
13 glioma susceptibility 1 29.7 TP53 PTEN PPARG MGMT MDM2 LZTR1
14 brain cancer 29.5 TP53 SYP SERPINA3 PTEN MGMT MDM2
15 gliosarcoma 28.6 TP53 TACC3 TACC1 SYP SERPINA3 SEPTIN14
16 glomangiomyoma 10.7 SYP CD34
17 lung meningioma 10.7 SYP CD34
18 fgfr craniosynostosis syndromes 10.7 FGFR3 FGFR1
19 desmoplastic infantile ganglioglioma 10.7 SYP GFAP
20 adult brain stem glioma 10.7 MGMT IDH1
21 aortic malignant tumor 10.7 MDM2 CD34
22 oligoastrocytoma 10.7 MGMT GFAP
23 benign pleural mesothelioma 10.7 TP53 CD34
24 third ventricle chordoid glioma 10.7 GFAP CD34
25 multifocal osteogenic sarcoma 10.7 TP53 CD34
26 glomangiosarcoma 10.7 SYP CD34
27 lung combined type small cell carcinoma 10.7 SYP GFAP
28 cerebral neuroblastoma 10.6 SYP GFAP
29 bile duct mucinous adenocarcinoma 10.6 TP53 SYP
30 sclerosing liposarcoma 10.6 MDM2 CD34
31 pediatric angiosarcoma 10.6 TP53 CD34
32 glomangiomatosis 10.6 TP53 SYP CD34
33 jejunal neoplasm 10.6 SYP CD34
34 plagiocephaly 10.6 FGFR3 FGFR1
35 exophthalmos 10.6 SYP FGFR3 CD34
36 ring chromosome 7 10.6 TP53 MDM2
37 breast duct papilloma 10.6 PTEN IDH1
38 polyploidy 10.6 TP53 AURKB
39 myoma 10.6 TP53 EGFR CD34
40 endobronchial leiomyoma 10.6 SYP GFAP CD34
41 epithelioid sarcoma 10.6 SYP EGFR CD34
42 deep leiomyoma 10.6 GFAP CD34
43 papillary adenofibroma 10.6 PTEN CD34
44 acinar cell cystadenocarcinoma 10.6 SYP SERPINA3
45 sarcomatoid transitional cell carcinoma 10.6 TP53 SYP
46 spindle cell liposarcoma 10.6 MDM2 CD34
47 chiari malformation 10.6 SYP GFAP FGFR3
48 pediatric liposarcoma 10.6 MDM2 CD34
49 clear cell meningioma 10.6 SYP GFAP CD34
50 glomus tumor 10.6 TP53 SYP CD34

Graphical network of the top 20 diseases related to Giant Cell Glioblastoma:



Diseases related to Giant Cell Glioblastoma
Sources

Symptoms & Phenotypes for Giant Cell Glioblastoma

About this section

UMLS symptoms related to Giant Cell Glioblastoma:


seizures, headache

GenomeRNAi Phenotypes related to Giant Cell Glioblastoma according to GeneCards Suite gene sharing:

26 (show all 17)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.64 EGFR
2 Decreased viability GR00055-A-2 9.64 EGFR
3 Decreased viability GR00173-A 9.64 AURKB
4 Decreased viability GR00221-A-1 9.64 AURKB EGFR FGFR1 FGFR3 PPARG
5 Decreased viability GR00221-A-2 9.64 AURKB FGFR1 FGFR3 PPARG
6 Decreased viability GR00221-A-3 9.64 FGFR3 PPARG
7 Decreased viability GR00221-A-4 9.64 AURKB EGFR PPARG
8 Decreased viability GR00249-S 9.64 AURKB FGFR3
9 Decreased viability GR00386-A-1 9.64 FGFR1 PPARG
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-111 9.56 MGMT
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-12 9.56 CD34
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-122 9.56 NFKBIA
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 9.56 NFKBIA
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-37 9.56 MGMT
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-59 9.56 MGMT
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 9.56 NFKBIA
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-72 9.56 MGMT

MGI Mouse Phenotypes related to Giant Cell Glioblastoma:

45 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.36 AURKB CD34 EGFR FGFR1 FGFR3 GFAP
2 homeostasis/metabolism MP:0005376 10.35 AURKB CD34 EGFR FGFR1 FGFR3 GFAP
3 growth/size/body region MP:0005378 10.32 AURKB EGFR FGFR1 FGFR3 GFAP IDH1
4 hematopoietic system MP:0005397 10.31 CD34 EGFR FGFR1 FGFR3 IDH1 LZTR1
5 immune system MP:0005387 10.27 CD34 EGFR FGFR1 FGFR3 GFAP IDH1
6 mortality/aging MP:0010768 10.24 AURKB EGFR FGFR1 FGFR3 GFAP IDH1
7 integument MP:0010771 10.21 AURKB CD34 EGFR FGFR1 FGFR3 MDM2
8 endocrine/exocrine gland MP:0005379 10.18 EGFR FGFR1 MDM2 MGMT NFKBIA PPARG
9 craniofacial MP:0005382 10.08 EGFR FGFR1 FGFR3 LZTR1 MDM2 TACC3
10 neoplasm MP:0002006 10 AURKB CD34 EGFR FGFR3 MDM2 MGMT
11 limbs/digits/tail MP:0005371 9.95 EGFR FGFR1 FGFR3 MDM2 PTEN TACC3
12 muscle MP:0005369 9.92 EGFR FGFR1 GFAP LZTR1 MDM2 PPARG
13 no phenotypic analysis MP:0003012 9.76 AURKB EGFR FGFR1 FGFR3 MDM2 MGMT
14 normal MP:0002873 9.7 EGFR FGFR1 FGFR3 GFAP MDM2 NFKBIA
15 skeleton MP:0005390 9.32 EGFR FGFR1 FGFR3 IDH1 LZTR1 MDM2
Sources

Drugs & Therapeutics for Giant Cell Glioblastoma

About this section

Drugs for Giant Cell Glioblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 304)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trioxsalen Approved Phase 3 3902-71-4 5585
2
Donepezil Approved Phase 3 120014-06-4 3152
3
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
4
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
5
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
6
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
7
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
8
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
9
Histamine Approved, Investigational Phase 3 51-45-6 774
10
Cyproheptadine Approved Phase 3 129-03-3 2913
11 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
12 Tubulin Modulators Phase 3
13 Antimitotic Agents Phase 3
14 Analgesics Phase 3
15 Photosensitizing Agents Phase 3
16 Dihematoporphyrin Ether Phase 3
17 Anesthetics Phase 3
18 Hematoporphyrins Phase 3
19 Anesthetics, General Phase 3
20 Hematoporphyrin Derivative Phase 3
21 Ether Phase 3
22 Anesthetics, Inhalation Phase 3
23 Cholinesterase Inhibitors Phase 3
24 Cholinergic Agents Phase 3
25 Liver Extracts Phase 3
26 Cola Phase 3
27 Narcotics Phase 3
28 Analgesics, Opioid Phase 3
29 Anesthetics, Intravenous Phase 3
30 Neurotransmitter Agents Phase 3
31 Central Nervous System Stimulants Phase 3
32 Dopamine Agents Phase 3
33 Dexmethylphenidate Hydrochloride Phase 3
34 Histamine Antagonists Phase 3
35 Anti-Allergic Agents Phase 3
36
Histamine Phosphate Phase 3 51-74-1 65513
37 Histamine H1 Antagonists Phase 3
38 Gastrointestinal Agents Phase 3
39
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
40
Ethanol Approved Phase 2 64-17-5 702
41
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
42
acetic acid Approved Phase 2 64-19-7 176
43
Sodium citrate Approved, Investigational Phase 2 68-04-2
44
Tamoxifen Approved Phase 2 10540-29-1 2733526
45
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
46
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
47
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
48
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
49
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60700
50
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314

Interventional clinical trials:

(show top 50) (show all 285)
# Name Status NCT ID Phase Drugs
1 Prospective Clinical Trials in the Use of Photodynamic Therapy (PDT) for the Treatment of Malignant Supratentorial Brain Tumors Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
2 A PHASE III TRIAL COMPARING THE USE OF RADIOSURGERY FOLLOWED BY CONVENTIONAL RADIOTHERAPY WITH BCNU TO CONVENTIONAL RADIOTHERAPY WITH BCNU FOR SUPRATENTORIAL GLIOBLASTOMA MULTIFORME Completed NCT00002545 Phase 3 carmustine
3 Randomized Study of Normal-fractionated Radiotherapy Versus Hypofractionated Radiotherapy Versus Chemotherapy in Patients Over 60 Years With Malignant Glioma Completed NCT00820963 Phase 3 temozolomide
4 Focal Fractionated Conformal Stereotactic Boost Following Conventional Radiotherapy of High Grade Gliomas: A Randomized Phase III Study Completed NCT00003916 Phase 3
5 A Randomized Prospective Two Arm Clinical Trial of High Light Dose And Low Light Dose PDT in the Treatment of Recurrent Malignant Supratentorial Gliomas Using Porfimer Sodium [Photofrin] Completed NCT00118222 Phase 3 porfimer sodium
6 Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
7 Concomitant and Adjuvant Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme - A Randomized Phase III Study Completed NCT00006353 Phase 3 temozolomide
8 A Phase III Randomized Study of SU101 Versus Procarbazine for Patients With Glioblastoma Multiforme in First Relapse Completed NCT00003293 Phase 3 leflunomide;procarbazine hydrochloride
9 A Prospective Randomised Trial Comparing Temozolomide With PCV In The Treatment Of Recurrent WHO Astrocytic Tumours Grades III And IV Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
10 A Phase III Study of Radiation Therapy (RT) and O6-Benzylguanine (O6-BG) Plus BCNU Versus RT and BCNU Alone for Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma Completed NCT00017147 Phase 3 carmustine;O6-Benzylguanine
11 Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT00304031 Phase 3 Concurrent temozolomide;100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle;75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle
12 A Randomized Phase III Study of Temozolomide and Short-Course Radiation Versus Short-Course Radiation Alone In The Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients Completed NCT00482677 Phase 3 temozolomide
13 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
14 A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
15 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
16 Phase III Randomized Evaluation of 13-Cis-Retinoic Acid (cRA) Plus Procarbazine Versus Procarbazine Alone in the Treatment of Patients With Recurrent Primary Malignant Gliomas Withdrawn NCT00003564 Phase 3 Isotretinoin;Procarbazine Hydrochloride
17 Phase II Study Trial Of Tarceva In Patients With Recurrent/Progressive Glioblastoma Multiforme Unknown status NCT00054496 Phase 2 erlotinib hydrochloride
18 A Phase I/II Trial of Conformal Radiotherapy and Hyperbaric Oxygen for Patients With Newly Diagnosed Glioblastoma Unknown status NCT00006460 Phase 1, Phase 2 hyperbaric oxygen
19 A Phase I/II Study of the Safety and Tolerability of DTI-015 in Patients With Recurrent Glioblastoma Multiforme Unknown status NCT00006656 Phase 2 carmustine in ethanol
20 Phase I/II Study of Intratumoral Injection of DTI-015 Prior to Tumor Resection in Patients With Recurrent Malignant Glioma or Metastatic Neoplasm to Brain Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
21 A Phase II Pilot Trial of Radiation Therapy With Concurrent and Adjuvant Temozolomide, Tamoxifen and Carboplatin (T2C) in the Treatment of Patients With Primary Central Nervous System Malignant Gliomas Unknown status NCT00492687 Phase 2 carboplatin;tamoxifen citrate;temozolomide
22 Phase II Trial of Bevacizumab in Combination With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly-diagnosed Glioblastoma Multiforme Unknown status NCT01013285 Phase 2 temozolomide
23 Phase I/II Trial of Temozolomide and Carboplatin in Recurrent Glioblastoma Multiforme Unknown status NCT00014105 Phase 1, Phase 2 carboplatin;temozolomide
24 Continuous Infusion Thiotepa in High Grade Astrocytic Tumors of Childhood and Adolescence A UKCCSG Phase II Study Involving the Brain Tumour and New Agent Groups Unknown status NCT00313521 Phase 2 thiotepa
25 A Prospective Phase II Trial of NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma Completed NCT01894061 Phase 2
26 Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme Completed NCT00423735 Phase 2 Dasatinib
27 A Phase 2 Study of R-(-)-Gossypol (Ascenta's AT-101) in Recurrent Glioblastoma Multiforme Completed NCT00540722 Phase 2 R-(-)-gossypol acetic acid
28 A Phase II Safety Study of Bevacizumab in Patients With Multiple Recurrent or Progressive Malignant Gliomas Completed NCT00337207 Phase 2
29 Phase II Trial of Intralesional Adoptive Cellular Therapy of Glioblastoma With Interleukin-2-Stimulated Lymphocytes Completed NCT00331526 Phase 2
30 A Phase II Trial of High Dose Tamoxifen For The Treatment of Newly Diagnosed Supratentorial Glioblastoma Multiforme (GBM) Completed NCT00006388 Phase 2 tamoxifen citrate
31 A Phase II Trial of Accelerated Radiotherapy Using Weekly Stereotactic Conformal Boosts For Supratentorial Glioblastoma Multiforme Completed NCT00006386 Phase 2 carmustine
32 Phase II Evaluation of Temozolomide (SCH52365) and Thalidomide for the Treatment of Recurrent and Progressive Glioblastoma Multiforme Completed NCT00006358 Phase 2 temozolomide;thalidomide
33 Open Label Phase II Study on RFS 2000 (9-Nitro-Camptothecin, 9-NC) Administered as a "5 Days On-2 Days Off" Oral Treatment in Glioblastoma Multiforme Completed NCT00005826 Phase 2 rubitecan
34 Phase II Trial of BCNU Plus O6-Benzylguanine in the Treatment of Patients With Recurrent or Progressive Cerebral Anaplastic Gliomas Completed NCT00005081 Phase 2 O6-benzylguanine;carmustine
35 Open Label Phase II Study on XR5000 Administered as a 5 Day Infusion in Patients With Glioblastoma Multiforme Completed NCT00004937 Phase 2 acridine carboxamide
36 A Randomized Double-Blind, Placebo-Controlled Phase II Study of the Matrix Metalloprotease Inhibitor Prinomastat in Combination With Temozolomide Following Radiation Therapy in Patients Having Newly Diagnosed Glioblastoma Multiforme Completed NCT00004200 Phase 2 prinomastat;temozolomide
37 Phase II Clinical and Pharmacologic Study of Radiation Therapy and CAI (Carboxy-Amido Triazole) in Adults With Newly Diagnosed Glioblastoma Multiforme Completed NCT00004146 Phase 2 carboxyamidotriazole
38 A Phase II Study of Temozolomide (SCH 52365, Temodal(R)) for the Treatment of Recurrent Malignant Glioma Completed NCT00004113 Phase 2 temozolomide
39 Phase II Study of Suramin and Concurrent Radiation Therapy in Newly Diagnosed Glioblastoma Multiforme Completed NCT00004073 Phase 2 suramin
40 Open Label Phase II Study On STI571 (Glivec) Administered As A Daily Oral Treatment In Gliomas Completed NCT00039364 Phase 2 imatinib mesylate
41 A Phase II Study of SarCNU (NSC 364432) in Patients With Malignant Glioma Completed NCT00036660 Phase 2 SarCNU
42 A Phase II Study of ZD 1839 (NSC 715055) for Patients With First Relapse Glioblastoma Multiforme Completed NCT00016991 Phase 2 gefitinib
43 A Phase II Study of CCI-779 in Patients With Recurrent Glioblastoma Multiforme Completed NCT00016328 Phase 2 temsirolimus
44 A Randomized, Dose-Ranging, Safety and Tolerability Study of NBI-3001 Administered by Continuous Intratumoral Infusion Followed by Surgical Resection in Patients With Recurrent Glioblastoma Multiforme Completed NCT00014677 Phase 2
45 Open Label Phase II Study On Glufosfamide Administered As A 60 Minute Infusion Every 3 Weeks In Recurrent Glioblastoma Multiforme Completed NCT00014300 Phase 2 glufosfamide
46 A Multi-Center, Open-Label Clinical Study to Evaluate the Safety and Performance of the Proxima GliaSite RTS, a Radiation Delivery System, in Patients With Recurrent Malignant Brain Tumors Undergoing Surgical Resection Completed NCT00003574 Phase 2
47 Phase II Treatment of Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme With Temodal Completed NCT00003464 Phase 2 temozolomide
48 A Phase II Trial of Paclitaxel and Topotecan With Filgrastim in Patients With Recurrent or Refractory Glioblastoma Multiforme or Anaplastic Astrocytoma Completed NCT00002814 Phase 2 paclitaxel;topotecan hydrochloride
49 ANALYSIS OF THE EFFICACY OF SURAMIN IN RECURRENT MALIGNANT PRIMARY BRAIN TUMORS Completed NCT00002639 Phase 2 chemotherapy;suramin
50 Phase II Study Of Temozolomide, Thalidomide And Celecoxib In Patients With Newly Diagnosed Glioblastoma Multiforme In The Post-Radiation Setting Completed NCT00047294 Phase 2 celecoxib;temozolomide;thalidomide

Search NIH Clinical Center for Giant Cell Glioblastoma

Sources

Genetic Tests for Giant Cell Glioblastoma

About this section
Sources

Anatomical Context for Giant Cell Glioblastoma

About this section

MalaCards organs/tissues related to Giant Cell Glioblastoma:

40
Brain, T Cells, Prostate, Eye, Bone, Spinal Cord, Liver
Sources

Publications for Giant Cell Glioblastoma

About this section

Articles related to Giant Cell Glioblastoma:

(show top 50) (show all 125)
# Title Authors PMID Year
1
Genetic profile of the giant cell glioblastoma. 54 61
10068201 1999
2
p53 mutations versus EGF receptor expression in giant cell glioblastomas. 61 54
9370234 1997
3
Update on Circumscribed Gliomas and Glioneuronal Tumors. 61
32389265 2020
4
Giant cell glioblastoma is a distinctive subtype of glioma characterized by vulnerability to DNA damage. 61
31655917 2020
5
Whole-exome sequencing revealed mutational profiles of giant cell glioblastomas. 61
30861589 2019
6
Association between giant cell glioblastoma and glioblastoma multiforme in the United States: A retrospective cohort study. 61
31464386 2019
7
Prognostic Factors and Treatment Patterns in the Management of Giant Cell Glioblastoma. 61
31009783 2019
8
Germline mutation p.N363K in POLE is associated with an increased risk of colorectal cancer and giant cell glioblastoma. 61
30368636 2019
9
Subgaleal and brain abscesses due to Salmonella enteritidis following craniotomy for giant cell glioblastoma multiforme: A case report and literature review. 61
31528375 2019
10
An Unusual Presentation of Spinal Giant Cell Glioblastoma in a 21-Year-Old Female. 61
31394931 2019
11
Imaging findings in the progression of a giant cell glioblastoma. 61
30128062 2018
12
Giant cell glioblastoma with spinal and spinal leptomeningeal metastasis in a child: A rare presentation of a rare tumor. 61
30783357 2018
13
Glioblastoma in the setting of prior lower grade gliomas - insights from SEER database. 61
30279958 2018
14
Giant cell glioblastoma with spinal and spinal leptomeningeal metastasis in a child: A rare presentation of a rare tumor. 61
30443141 2018
15
Acute lymphoblastic leukemia following temozolomide treatment in a patient with glioblastoma: A case report and review of the literature. 61
29805603 2018
16
Risk of subsequent cancer among pediatric, adult and elderly patients following a primary diagnosis of glioblastoma multiforme: a population-based study of the SEER database. 61
28288541 2017
17
IDH-mutant giant cell glioblastoma: A neglected tumor variant? 61
29035191 2017
18
Giant Cell Glioblastoma in a Child with Clinical and Family History of Neurofibromatosis. 61
29114311 2017
19
Intraventricular gliosarcoma with dual sarcomatous differentiation: A unique case. 61
28261869 2017
20
Radiologic Dilemma in an Extra-Axial Petroclival Lesion: Low Grade versus High Grade. 61
28109858 2017
21
Incidence, survival, pathology, and genetics of adult Latino Americans with glioblastoma. 61
28161760 2017
22
Genetic Alterations in Gliosarcoma and Giant Cell Glioblastoma. 61
26443480 2016
23
Intraoperative Squash Cytologic Features of Subependymal Giant Cell Astrocytoma. 61
27013816 2016
24
MGMT Promoter Methylation and BRAF V600E Mutations Are Helpful Markers to Discriminate Pleomorphic Xanthoastrocytoma from Giant Cell Glioblastoma. 61
27253461 2016
25
Pediatric Giant Cell Glioblastoma Mimicking Hemorrhage Secondary to Ischemic Stroke. 61
26344331 2015
26
Giant cell glioblastoma with calcification and long-term survival. 61
26960525 2015
27
A spontaneously occurring malignant pituicytoma in a male sprague dawley rat. 61
26441479 2015
28
Adult classical glioblastoma with a BRAF V600E mutation. 61
25885250 2015
29
Survival outcomes of giant cell glioblastoma: institutional experience in the management of 20 patients. 61
25037316 2014
30
Treatment and survival of patients harboring histological variants of glioblastoma. 61
24980627 2014
31
[Gliosarcoma of cerebral hemispheres: a clinicopathologic study of 10 cases]. 61
25567590 2014
32
Estimating the surface area of nonconvex particles from central planar sections. 61
24832486 2014
33
Cerebellar giant cell glioblastoma multiforme in an adult. 61
25002780 2014
34
BRAF-mutated pleomorphic xanthoastrocytoma is associated with temporal location, reticulin fiber deposition and CD34 expression. 61
24345274 2014
35
Giant-cell glioblastoma of childhood associated with HIV-1 and JC virus coinfection. 61
23702739 2013
36
Epithelioid GBMs show a high percentage of BRAF V600E mutation. 61
23552385 2013
37
Recurrent giant cell glioblastoma with the neuroradiologic picture of multiple meningiomas. 61
22241593 2013
38
Giant cell glioblastoma in the pediatric age group: Report of two cases. 61
23772243 2013
39
Giant cell glioblastoma with unique bilateral cerebellopontine angle localization considered as extraaxial tumor growth in a patient with neurofibromatosis Type 1. 61
22943956 2013
40
Magnetic resonance imaging and computed tomography findings in pediatric giant cell glioblastoma. 61
22286149 2012
41
Giant cell glioblastoma in a child: A rare case report. 61
23293671 2012
42
Cytomorphology of giant cell glioblastoma: Report of a case and brief review of literature. 61
21319330 2012
43
Highly malignant behavior of a murine oligodendrocyte precursor cell line following transplantation into the demyelinated and nondemyelinated central nervous system. 61
22420305 2012
44
Glioblastoma multiforme in children: report of 13 cases and review of the literature. 61
21824566 2011
45
Acute tetraplegia and cardiac arrest following high cervical leptomeningeal metastasis of giant cell glioblastoma. 61
21658953 2011
46
Giant cell glioblastoma in the cerebrum of a Pembroke Welsh corgi. 61
21146179 2011
47
Intraventricular pleomorphic xanthoastrocytoma with anaplastic features. 61
20051018 2010
48
A case of giant cell glioblastoma: a mimicker of a cerebral metastasis. 61
20973333 2010
49
Giant cell glioblastoma is associated with altered aurora b expression and concomitant p53 mutation. 61
20467329 2010
50
CD34 expression in glioblastoma and giant cell glioblastoma. 61
20175958 2010
Sources

Variations for Giant Cell Glioblastoma

About this section
Sources

Expression for Giant Cell Glioblastoma

About this section
Search GEO for disease gene expression data for Giant Cell Glioblastoma.
Sources

Pathways for Giant Cell Glioblastoma

About this section

Pathways related to Giant Cell Glioblastoma according to GeneCards Suite gene sharing:

(show all 35)
# Super pathways Score Top Affiliating Genes
1
Class I MHC mediated antigen processing and presentation 65
Show member pathways
 13.39 TP53 PTEN NFKBIA MDM2 FGFR3 FGFR1
2
GAB1 signalosome 65
Show member pathways
 13.06 TP53 PTEN MDM2 FGFR3 FGFR1 EGFR
3
Phospholipase-C Pathway 63
Show member pathways
 13.02 TP53 PTEN MDM2 FGFR3 FGFR1 EGFR
4
PI3K-Akt signaling pathway 36
Show member pathways
 12.92 TP53 PTEN MDM2 FGFR3 FGFR1 EGFR
5
Endometrial cancer 36
Show member pathways
 12.72 TP53 PTEN PPARG NFKBIA MDM2 FGFR1
6
Glioma 36
Show member pathways
 12.63 TP53 PTEN MDM2 FGFR1 EGFR
7
ErbB signaling pathway 36 1
Show member pathways
 12.55 TP53 PTEN MDM2 FGFR3 EGFR
8
Downstream signaling events of B Cell Receptor (BCR) 65
Show member pathways
 12.51 TP53 PTEN NFKBIA MDM2 FGFR3 FGFR1
9
Pathways in cancer 36
12.48 TP53 PTEN PPARG NFKBIA MDM2 FGFR3
10
MicroRNAs in cancer 36
12.44 TP53 PTEN MDM2 FGFR3 EGFR
11
DNA Damage 4
12.39 TP53 TACC3 MGMT MDM2 AURKB
12
mTOR signaling pathway (KEGG) 36
Show member pathways
 12.38 TP53 PTEN FGFR3 FGFR1 EGFR
13
VEGF Signaling 66
Show member pathways
 12.35 TP53 PTEN MDM2 FGFR3 FGFR1 EGFR
14
Shigellosis 36
12.34 TP53 NFKBIA MDM2 EGFR
15
Development IGF-1 receptor signaling 22
Show member pathways
 12.34 TP53 PTEN NFKBIA MDM2
16
Apoptosis Pathway 70
Show member pathways
 12.27 TP53 NFKBIA MDM2 FGFR3 FGFR1 EGFR
17
Translation Non-genomic (rapid) action of Androgen Receptor 22
Show member pathways
 12.26 TP53 PTEN MDM2 EGFR
18
Proteoglycans in cancer 36
12.25 TP53 MDM2 FGFR1 EGFR
19
G-protein signaling Ras family GTPases in kinase cascades (scheme) 22
Show member pathways
 12.24 TP53 PPARG NFKBIA EGFR
20
MAPK Signaling: Mitogens 64
Show member pathways
 12.12 TP53 PTEN MDM2 FGFR3 FGFR1 EGFR
21
Integrated Breast Cancer Pathway 1
12.06 TP53 PTEN MDM2 EGFR
22
Direct p53 effectors 1
11.96 TP53 PTEN MDM2 EGFR
23
Retinoblastoma (RB) in Cancer 1
11.79 TP53 POLE MDM2
24
ATM Pathway 63
Show member pathways
 11.78 TP53 NFKBIA MDM2
25
Glioblastoma Multiforme 63
11.7 TP53 PTEN MGMT MDM2 EGFR
26
Neural Stem Cells and Lineage-specific Markers 64
11.69 SYP GFAP FGFR3 FGFR1
27
Bladder cancer 36 1
11.64 TP53 MDM2 FGFR3 EGFR
28
Proteolysis Putative SUMO-1 pathway 22
Show member pathways
 11.54 TP53 NFKBIA MDM2
29
Copper homeostasis 1
11.53 TP53 PTEN MDM2
30
Integrated Cancer Pathway 1
11.43 TP53 PTEN MDM2
31
Alzheimers Disease Pathway 63
11.41 FGFR3 FGFR1 EGFR
32
DNA damage_ATM/ATR regulation of G1/S checkpoint 22
11.39 TP53 NFKBIA MDM2
33
Vemurafenib Pathway, Pharmacodynamics 60
11.37 FGFR3 FGFR1 EGFR
34
Central carbon metabolism in cancer 36
11.28 TP53 PTEN IDH1 FGFR3 FGFR1 EGFR
35
Aurora A signaling 1
10.59 TP53 TACC3 TACC1 NFKBIA MDM2 AURKB
Sources

GO Terms for Giant Cell Glioblastoma

About this section

Cellular components related to Giant Cell Glioblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.5 TP53 TACC3 TACC1 SEPTIN14 PTEN PPARG

Biological processes related to Giant Cell Glioblastoma according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 heart development GO:0007507 9.85 TP53 PTEN PPARG MDM2
2 regulation of cell proliferation GO:0042127 9.76 TP53 NFKBIA FGFR1 EGFR
3 positive regulation of kinase activity GO:0033674 9.67 FGFR3 FGFR1 EGFR
4 protein autophosphorylation GO:0046777 9.67 FGFR3 FGFR1 EGFR AURKB
5 response to drug GO:0042493 9.65 TP53 PTEN PPARG MGMT MDM2
6 negative regulation of neuron projection development GO:0010977 9.61 PTEN MDM2 GFAP
7 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.54 TP53 EGFR
8 negative regulation of telomerase activity GO:0051974 9.52 TP53 PPARG
9 salivary gland morphogenesis GO:0007435 9.51 FGFR1 EGFR
10 mitotic spindle organization GO:0007052 9.5 TACC3 TACC1 AURKB
11 positive regulation of phospholipase activity GO:0010518 9.48 FGFR3 FGFR1
12 negative regulation of apoptotic process GO:0043066 9.43 TP53 PTEN NFKBIA MGMT MDM2 EGFR
13 cellular response to UV-C GO:0071494 9.4 TP53 MDM2
14 cellular response to actinomycin D GO:0072717 9.16 TP53 MDM2
15 response to organic cyclic compound GO:0014070 9.02 PTEN PPARG MGMT IDH1 EGFR

Molecular functions related to Giant Cell Glioblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein self-association GO:0043621 9.5 TP53 SYP PPARG
2 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.43 FGFR3 FGFR1 EGFR
3 enzyme binding GO:0019899 9.43 TP53 PTEN PPARG NFKBIA MDM2 EGFR
4 peroxisome proliferator activated receptor binding GO:0042975 9.37 TACC1 MDM2
5 identical protein binding GO:0042802 9.36 TP53 SYP PTEN PPARG NFKBIA MDM2
6 fibroblast growth factor-activated receptor activity GO:0005007 9.16 FGFR3 FGFR1
Sources

Sources for Giant Cell Glioblastoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....